Cue Biopharma (NASDAQ:CUE – Get Free Report) and Tenax Therapeutics (NASDAQ:TENX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Profitability
This table compares Cue Biopharma and Tenax Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cue Biopharma | -59.65% | -98.30% | -53.69% |
| Tenax Therapeutics | N/A | -56.32% | -53.12% |
Earnings and Valuation
This table compares Cue Biopharma and Tenax Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Biopharma | $27.47 million | 4.37 | -$26.60 million | ($5.58) | -5.13 |
| Tenax Therapeutics | N/A | N/A | -$52.60 million | ($1.40) | -8.57 |
Cue Biopharma has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 3.1% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Cue Biopharma has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Cue Biopharma and Tenax Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Tenax Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Tenax Therapeutics has a consensus price target of $39.67, indicating a potential upside of 230.56%. Given Tenax Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Cue Biopharma.
Summary
Tenax Therapeutics beats Cue Biopharma on 8 of the 14 factors compared between the two stocks.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
About Tenax Therapeutics
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
